Combined Ultrasound Hepatic and Renal Denervation for Essential Hypertension (uHRDN)

November 11, 2026 updated by: Shanghai Hantong Medical Technology Co., LTD

Safety, Efficacy, and Clinical Feasibility of an Ultrasound Denervation System in Subjects With Essential Hypertension: A Prospective, Multicenter, Open-Label, Single-Arm, Exploratory Study

This study will evaluate the safety and feasibility of a procedure that uses ultrasound energy to treat nerves around the arteries that supply the kidneys and liver. It will also assess whether blood pressure changes after the procedure in people whose high blood pressure remains inadequately controlled despite medication.

All participants who qualify will receive the study procedure. The study team will check for major safety events during the procedure and through 30 days afterward. The team will also compare the average systolic blood pressure measured over 24 hours before the procedure and at the 6-month follow-up.

The study will also look at changes in blood pressure medications and, for participants with type 2 diabetes, changes in blood sugar control.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

This is a prospective, multicenter, open-label, single-arm exploratory study with a planned enrollment of 10 participants. The study includes participants with essential hypertension that remains inadequately controlled after at least 4 weeks of fixed-dose combination antihypertensive therapy. Participants may have hypertension with or without type 2 diabetes.

Before the procedure, computed tomography angiography or magnetic resonance angiography is used to assess vascular anatomy. Digital subtraction angiography is used during the procedure to confirm anatomical suitability. The investigational system consists of a single-use ultrasound ablation catheter and an ultrasound ablation generator. Treatment targets the main renal arteries and the main trunk of the common hepatic artery. First-order renal artery branches may also be treated if their anatomy meets the device requirements.

The study will summarize safety, blood pressure changes, and procedural feasibility descriptively. Measures of glucose metabolism will be explored in participants with type 2 diabetes.

Study Type

Interventional

Enrollment (Estimated)

10

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Age 18 to 75 years, inclusive.

  2. Diagnosed with essential hypertension and inadequately controlled blood pressure, with or without type 2 diabetes mellitus (T2DM).

  3. After providing informed consent and after the investigator confirms that switching therapy is safe, participants must take study-supplied amlodipine 5 mg/day and irbesartan 150 mg/day. After at least 28 days of standardized therapy, office systolic blood pressure must be at least 150 mmHg and less than 180 mmHg, and mean 24-hour ambulatory systolic blood pressure must be at least 135 mmHg and less than 170 mmHg, as confirmed by ambulatory blood pressure monitoring.

  4. Participants with T2DM must meet all of the following:

    • Body mass index of at least 24 kg/m².
    • HbA1c of 7.0% to 9.0% at screening or within the preceding 3 months, and again on preprocedural retesting at Visit 3.
    • No changes in the types or doses of glucose-lowering medications for at least 4 weeks before Visit 3. In principle, the regimen should remain stable until completion of the 6-month primary endpoint assessment.

Exclusion Criteria:

  1. Anatomy of either main renal artery or the main trunk of the common hepatic artery unsuitable for study treatment. Unsuitability of first-order renal artery branches for additional treatment is permitted.

  2. Any of the following on preprocedural computed tomography angiography, magnetic resonance angiography, or renal angiography:

    • Greater than 50% diameter stenosis in either main renal artery or the common hepatic artery.
    • Diameter less than 3 mm or greater than 8 mm in either main renal artery or the common hepatic artery.
  3. Previous renal artery denervation or hepatic artery denervation.

  4. History of New York Heart Association (NYHA) class III or IV heart failure within 6 months before screening.

  5. Stroke or transient ischemic attack within 6 months before screening, or any prior stroke resulting in permanent disability.

  6. Type 1 diabetes mellitus, or insulin use within 6 months before screening in participants with T2DM.

  7. Secondary hypertension.

  8. Estimated glomerular filtration rate below 40 mL/min/1.73 m², calculated using the 2021 CKD-EPI creatinine equation.

  9. Pregnancy, breastfeeding, or planned pregnancy during the study.

  10. Severe concomitant respiratory disease requiring long-term oxygen therapy or mechanical ventilation.

  11. History or evidence of active or suspected chronic liver or biliary tract disease.

  12. Current or previous chronic pancreatitis.

  13. Active severe infection, a marked bleeding tendency, or inability to receive perioperative anticoagulant or antiplatelet therapy.

  14. Any other condition that, in the investigator's judgment, precludes participation in the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Combined Ultrasound Hepatic and Renal Denervation

All enrolled participants receive combined ultrasound hepatic and renal denervation using the investigational ultrasound denervation system.

The investigational system consists of a single-use ultrasound ablation catheter (model HR35-1050) and an ultrasound ablation generator (model U10-HR). The system delivers ultrasound energy for denervation along the main renal arteries and the main trunk of the common hepatic artery. First-order renal artery branches may also be treated if their anatomy meets the device requirements.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change From Baseline in Mean 24-Hour Ambulatory Systolic Blood Pressure
Time Frame: Baseline (Visit 2) and 6 months after the procedure

Change in mean 24-hour systolic blood pressure, measured by ambulatory blood pressure monitoring and reported in mmHg. Change is calculated as the 6-month value minus the baseline (Visit 2) value.

Baseline (Visit 2) and 6 months after the procedure
Incidence of the composite endpoint of major safety events within 30 days after the procedure.
Time Frame: From vascular puncture at the start of the procedure through postprocedure Day 30, inclusive

Percentage of participants with at least one prespecified event: all-cause death, access-site complications requiring transfusion or invasive intervention or causing or prolonging hospitalization, target artery complications requiring intervention, new myocardial infarction, stroke, transient ischemic attack or other fatal, life-threatening or hospitalization-requiring cardiovascular or cerebrovascular events, acute kidney injury requiring dialysis or other serious renal events causing or prolonging hospitalization, acute liver failure or serious liver injury causing or prolonging hospitalization, acute pancreatitis, biliary tract or gallbladder complications requiring hospitalization or intervention, or other serious adverse events related to the device or procedure. Event relatedness to the device and to the procedure is assessed separately.

From vascular puncture at the start of the procedure through postprocedure Day 30, inclusive

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change From Baseline in Office Systolic Blood Pressure
Time Frame: Baseline (Visit 2) and 6 months after the procedure

Change in office systolic blood pressure, reported in mmHg, calculated as the 6-month value minus the baseline (Visit 2) value.

Baseline (Visit 2) and 6 months after the procedure
Change From Baseline in Office Diastolic Blood Pressure
Time Frame: Baseline (Visit 2) and 6 months after the procedure

Change in office diastolic blood pressure, reported in mmHg, calculated as the 6-month value minus the Visit 2 value.

Baseline (Visit 2) and 6 months after the procedure
Change From Baseline in Mean 24-Hour Ambulatory Diastolic Blood Pressure
Time Frame: Baseline (Visit 2) and 6 months after the procedure

Change in mean 24-hour diastolic blood pressure measured by ambulatory blood pressure monitoring (ABPM), reported in mmHg.

Baseline (Visit 2) and 6 months after the procedure
Change From Baseline in Mean Daytime Ambulatory Systolic Blood Pressure
Time Frame: Baseline (Visit 2) and 6 months after the procedure

Change in mean daytime systolic blood pressure measured by ABPM, reported in mmHg.

Baseline (Visit 2) and 6 months after the procedure
Change From Baseline in Mean Daytime Ambulatory Diastolic Blood Pressure
Time Frame: Baseline (Visit 2) and 6 months after the procedure

Change in mean daytime diastolic blood pressure measured by ABPM, reported in mmHg.

Baseline (Visit 2) and 6 months after the procedure
Change From Baseline in Mean Nighttime Ambulatory Systolic Blood Pressure
Time Frame: Baseline (Visit 2) and 6 months after the procedure

Change in mean nighttime systolic blood pressure measured by ABPM, reported in mmHg.

Baseline (Visit 2) and 6 months after the procedure
Change From Baseline in Mean Nighttime Ambulatory Diastolic Blood Pressure
Time Frame: Baseline (Visit 2) and 6 months after the procedure

Change in mean nighttime diastolic blood pressure measured by ABPM, reported in mmHg.

Baseline (Visit 2) and 6 months after the procedure
Proportion of Participants With Controlled Office Systolic Blood Pressure
Time Frame: 6 months after the procedure

Percentage of participants with office systolic blood pressure below 140 mmHg at 6 months.

6 months after the procedure
Change From Baseline in the Composite Antihypertensive Medication Index
Time Frame: Baseline (Visit 2) and 6 months after the procedure

Change in the protocol-defined composite antihypertensive medication index from Visit 2 to 6 months.

Baseline (Visit 2) and 6 months after the procedure
Change From Baseline in Glycated Hemoglobin in Participants With Type 2 Diabetes
Time Frame: Baseline (Visit 3) and 6 months after the procedure

Change in glycated hemoglobin (HbA1c), reported in percentage points, in participants with concomitant type 2 diabetes.

Baseline (Visit 3) and 6 months after the procedure
Change From Baseline in Fasting Plasma Glucose in Participants With Type 2 Diabetes
Time Frame: Baseline (Visit 3) and 6 months after the procedure

Change in fasting plasma glucose in participants with concomitant type 2 diabetes.

Baseline (Visit 3) and 6 months after the procedure
Changes in Glucose-Lowering Medication Use in Participants With Type 2 Diabetes
Time Frame: Baseline (Visit 3) and 6 months after the procedure

Changes in the types and doses of glucose-lowering medications in participants with concomitant type 2 diabetes.

Baseline (Visit 3) and 6 months after the procedure
Device Success Rate
Time Frame: During the procedure through device withdrawal

Percentage of participants with successful device delivery, completion of planned energy delivery, and safe device withdrawal, without a device malfunction that prevents treatment completion.

During the procedure through device withdrawal
Procedural Success Rate
Time Frame: During the procedure through procedure completion

Percentage of participants in whom the intended ablation is completed at anatomically appropriate sites, including at least two sites in total across both kidneys and at least one site in the common hepatic artery, with the intended procedural objective achieved and no serious intraprocedural complications.

During the procedure through procedure completion
Incidence of New Target Artery Stenosis or Vascular Lesions Requiring Intervention
Time Frame: 6 months after the procedure

Percentage of participants with new diameter stenosis greater than 70% in a main renal artery, a treated first-order renal artery branch, or the main trunk of the common hepatic artery, or with a relevant vascular lesion requiring intervention. Assessed by computed tomography angiography, magnetic resonance angiography, or digital subtraction angiography if needed.

6 months after the procedure
Proportion of Participants With at Least a 30% Decline in Estimated Glomerular Filtration Rate
Time Frame: Baseline and 6 months after the procedure, with repeat testing within 7 days of a qualifying result

Percentage of participants with a decline of at least 30% in estimated glomerular filtration rate from baseline. The first qualifying result is confirmed by repeat testing within 7 days, after excluding clearly reversible causes.

Baseline and 6 months after the procedure, with repeat testing within 7 days of a qualifying result
Changes From Baseline in Hepatobiliary Laboratory Parameters
Time Frame: Baseline (Visit 3) and 6 months after the procedure

Changes in alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, gamma-glutamyl transferase, total bilirubin, and direct bilirubin.

Baseline (Visit 3) and 6 months after the procedure
Incidence of Hepatobiliary Complications
Time Frame: Assessed at 6 months after the procedure

Incidence of acute liver injury, biliary stricture or obstruction, acute cholecystitis, and other hepatobiliary complications requiring hospitalization or clinical intervention.

Assessed at 6 months after the procedure
Changes From Baseline in Amylase and Lipase
Time Frame: Baseline and 6 months after the procedure

Changes in amylase and lipase from baseline to 6 months.

Baseline and 6 months after the procedure
Incidence of Adverse Events Through 6 Months
Time Frame: From the start of the procedure through 6 months

Percentage of participants with at least one adverse event.

From the start of the procedure through 6 months
Incidence of Serious Adverse Events Through 6 Months
Time Frame: From the start of the procedure through 6 months

Percentage of participants with at least one serious adverse event.

From the start of the procedure through 6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Principal Investigator: Junbo Ge, hongshan Hospital, Fudan University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 30, 2026

Primary Completion (Estimated)

December 30, 2027

Study Completion (Estimated)

March 30, 2028

Study Registration Dates

First Submitted

November 11, 2026

First Submitted That Met QC Criteria

November 11, 2026

First Posted (Actual)

November 17, 2026

Study Record Updates

Last Update Posted (Actual)

November 17, 2026

Last Update Submitted That Met QC Criteria

November 11, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • HT-CT-2601-FIM

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

The sponsor does not plan to share individual participant data (IPD) from this study with other researchers.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.